The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.
Administered subcutaneously
Administered subcutaneously
Bahía Blanca, Argentina
Buenos Aires, Argentina
Cipolletti, Argentina
Ciudad de Parana, Argentina
Coronel Suárez, Argentina
Corrientes, Argentina
Córdoba, Argentina
Junín, Argentina
La Plata, Argentina
Mar del Plata, Argentina
Merlo, Argentina
Quilmes, Argentina
Rafaela Santa Fe, Argentina
Rosario, Argentina
Salta, Argentina
San Miguel de Tucumán, Argentina
San Nicolás, Argentina
Santa Fe, Argentina
Venado Tuerto, Argentina
Villa María, Argentina
Zárate, Argentina